New shot could clear teen psoriasis – trial underway
NCT ID NCT07265284
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called picankibart in teenagers aged 12 to 18 with moderate-to-severe plaque psoriasis. Half get the drug, half get a placebo, and researchers check if their skin clears up after 16 weeks. The goal is to see if it's safe and works better than a dummy treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Children's Hospital Affiliated to Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
picankibart (IBI112)
What this could lead to
If it works, this could offer a new treatment option for teenagers with stubborn psoriasis, helping clear skin and improve quality of life.
What could go wrong
This is still an early-stage trial with only 104 participants, so results may not apply to everyone. As with any drug, there are risks of side effects like infections or allergic reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.